NCT02126579 2024-02-28
MEL60
University of Virginia
Phase 1/2 Completed
Clinical Trials
10 trialsNCT00960752 2021-08-13
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00948961 2016-06-27
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Celldex Therapeutics
Phase 1/2 Completed
NCT00821652 2015-01-08
Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT00470379 2014-10-31
Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT00114920 2007-02-19
Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults
Graceway Pharmaceuticals, LLC
Phase 2 Completed
NCT00115141 2007-02-19
Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults
Graceway Pharmaceuticals, LLC
Phase 2 Completed
NCT00116662 2007-02-19
An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
Graceway Pharmaceuticals, LLC
Phase 2 Completed
NCT00116675 2007-02-19
Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
Graceway Pharmaceuticals, LLC
Phase 2 Completed
NCT00117923 2007-02-19
Study With a Topical Gel to Treat Common Warts in Adults
Graceway Pharmaceuticals, LLC
Phase 2 Completed